In the last few years the effectiveness of CGM in T1D and T2D insulin-treated was widely studied; it has been demonstrated that both T1D and T2D insulin-treated patients in MDI who used CGM improve glycemic control and quality of life compared to those using SMBG [63,64,65]. The gene discussed is INS; the disease is type 2 diabetes mellitus.